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Abstract
Background: Most studies of men undergoing treatment for prostate cancer examine physical symptoms as predictors
of Quality of Life (QOL). However, symptoms vary by treatment modality in this population, and psychosocial variables,
shown to be important to QOL, have rarely been examined. Litwin noted a need for analysis of QOL data in men treated
for prostate cancer with different modes of therapy, as studies focusing on specific treatments will increase the
homogeneity of research findings.
Methods: This cross-sectional study explored physical and psychosocial predictors of QOL in men receiving one of two
types of radiation treatment for prostate cancer: Intensity Modulated Radiation Therapy (IMRT) + High Dose Rate
(HDR) Brachytherapy or IMRT + seed implantation. Subjects completed a biographic questionnaire; quality of life
measures, which were the eight subscales of the Medical Outcome Study Short Form Health Survey (SF-36); measures
of physical symptoms including the Radiation Therapy Oncology Group and the European Organization for Research and
Treatment of Cancer (RTOG/EORTC) and the Prostate Symptom Self-Report (PSSR); and measures of psychological
factors, the Ways of Coping Scale (WOC), Perceived Stress Scale, the Anxiety Subscale of the SCL-90, and Strategies
Used by Patients to Promote Health (SUPPH). Eight regression models including both physical and psychosocial variables
were used to predict quality of life.
Results: Sixty-three subjects with complete data on all variables were studied. Treatment effect sizes were medium to
large in predicting each of the quality of life subscales of the SF-36. Psychosocial variables were related to physical
function, role function, bodily pain, general health, social function, emotional role, and mental health. Physical symptoms
were related to subjects' perceived general health and mental health.
Discussion: The number of significant relationships among psychosocial variables and indicators of QOL exceeded the
number of relationships among symptoms and QOL suggesting that psychosocial variables associate strongly with
prostate cancer patients' reports of quality of life. Findings of the study may provide patients and families with knowledge
that contributes to their understanding of quality of life outcomes of IMRT+ HDR and IMRT + seed implantation and
their ability to make more informed treatment choices.
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Background
Prostate cancer is the most common cancer and the sec-
ond leading cause of cancer deaths in men in the United
States http://www.cancer.org. It is estimated that in 2004,
230,110 men in the U.S. will be diagnosed with prostate
cancer (PCa) and 29,900 will die of the disease. The 5-year
overall relative survival rate for prostate cancer increased
from 79.6% between 1983–90 to 98% in 2004. More than
75% of men diagnosed with prostate cancer are over age
65. In view of decreasing death rates, medical treatments
for cancer patients are increasingly being evaluated by
quality of life (QOL) issues as well as life extension [1].
Psychometric assessment and decision theory are the two
main approaches used to study QOL [2]. The psychomet-
ric approach theorizes separate dimensions and measures
for QOL, and the SF-36 is a tool frequently used in this
approach. In the decision theory approach, various
dimensions of health are weighted in order to provide a
single holistic index of QOL. Health-related QOL is a mul-
tidimensional construct that reflects the impact of illness
and treatment on physical, psychological, social and func-
tional dimensions of well being [3].
Men undergoing treatment for prostate cancer report neg-
ative physiological and psychological health effects. The
varied symptoms reported may be a function of the cancer
itself, or the type of therapy received; or the symptoms
may have been present prior to the development of pros-
tate cancer and receipt of treatment. A recent study exam-
ined quality of life related to bowel, bladder and sexual
symptoms in men receiving treatment for PCa. Partici-
pants were not examined by treatment type and psycho-
logical variables were not included in the study.
Researchers found that the strongest predictors of poor
QOL were bowel, sexual and urinary symptoms respec-
tively [4].
Eton and Lepore [5] reviewed several studies of symptoms
associated with treatment for localized PCa. Urinary and
bowel dysfunction were found to be the result of treat-
ment. Urinary function was most affected in men who
were treated with radical prostatectomy compared to
those receiving external beam radiation with or without
brachytherapy, hormone therapy or those treated with
observation alone. Bowel function was most affected by
external beam radiotherapy and brachytherapy. In the
same review, researchers reported that sexual problems
were related to the disease and were exacerbated by treat-
ment, particularly standard radical prostatectomy.
Although psychological variables have been shown to be
more important than treatment morbidity to the QOL of
patients with prostate cancer, most studies of patients
with prostate cancer continue to focus on symptoms such
as urinary, bowel and sexual dysfunction [6]. The ability
of prostate cancer patients to maintain psychosocial func-
tioning and healthy psychological states (e.g., freedom
from mood distress or excessive anxiety) has been less fre-
quently considered [6]. The experience of living with can-
cer, from the time of diagnosis and treatment decisions,
through treatment itself and survival is fraught with psy-
chological distress. Increased attention to mood is
reflected in chronic illness literature describing effects of
mood on health related quality of life [7].
Perceived stress is based on the relationship between the
person and environment. It is the degree to which the
individual appraises events as unpredictable, uncontrolla-
ble, and overloading. Perceived stress drives the coping
response [8]. Coping is defined as one's response to per-
ceived external stressors. Two types of coping have been
conceptualized: Problem-Focused Coping and Emotion-
Focused Coping. Problem-Focused Coping refers to those
actions taken to resolve the environmental stressor. Emo-
tion-Focused Coping refers to efforts taken by the individ-
ual to mediate the emotional responses to the stressor [8].
Anxiety and the ability to cope with cancer are influenced
by perceptions. These include the meaning men give to
prostate cancer and its treatment and the way these factors
impact their lives. Roth and associates [9] reported on a
sample of men receiving treatment for PCa and screened
for anxiety and depression using the Hospital Anxiety and
Depression Scale. Thirty-two percent of patients with PCa
scored at or above the anxiety cutoff score.
Bandura [10] asserted that psychosocial variables, such as
self-efficacy, strongly influence the perceived quality of
one's life. Self-efficacy is described as the coordinator of
psychological change, operating by changing expectancies
of personal mastery. Robust efficacy beliefs may help to
marshal coping responses that reduce stress and anxiety.
Peoples' self-efficacy may regulate their emotional states
in several ways. People who believe they can manage
threats are less distressed by them; those who lack self-effi-
cacy are more likely to magnify risks. People with high
self-efficacy lower their stress and anxiety by acting in
ways that make the environment less threatening. People
with high coping capacities have better control over dis-
turbing thought.
Litwin [11] noted a need for the study of QOL and indica-
tors of adjustment in men treated for prostate cancer. He
suggested using three types of measures: a generic measure
of health, a measure of symptoms specific to prostate can-
cer, and psychosocial measures. Litwin [11] also noted a
need for the study of QOL in men receiving different treat-
ments for PCa in order to improve the specificity of
research findings.Health and Quality of Life Outcomes 2004, 2 http://www.hqlo.com/content/2/1/28
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Intensity Modulated Radiation Therapy (IMRT) is a new
technology in radiation oncology that delivers radiation
more precisely to the tumor and is more sparing of sur-
rounding normal tissues. IMRT has wide application in
most aspects of radiation oncology because of its ability to
create multiple targets and multiple avoidance structures,
to treat different targets simultaneously at different doses,
as well as to weight targets and avoidance structures
according to their importance. By delivering radiation
with greater precision, IMRT has been shown to minimize
acute treatment-related morbidity, making dose escala-
tion feasible, which may ultimately improve local tumor
control [12]. Furthermore, IMRT can be combined with
brachytherapy and High Dose Rate (HDR).
Brachytherapy is a prostate cancer (PCa) treatment in
which radioactive sources are implanted into the prostate
gland. The most commonly performed brachytherapy
treatment is permanent radioactive seed implantation.
This out-patient, minimally invasive procedure is per-
formed by inserting small needles through the perineum
into the prostate gland under ultrasound visualization.
Radioactive Palladium or Iodine seeds are then injected
through the needles. These low energy radioactive sources
have limited tissue penetration allowing for a sharp drop-
off at the edge of the gland, thus limiting radiation deliv-
ery to normal tissues. The precision and conformation of
the brachytherapy dose allows a much higher dose to be
delivered to the prostate gland than can be delivered with
external beam radiation (IMRT + seed implantation).
Another form of brachytherapy that has been used to treat
PCa is high dose rate brachytherapy (HDR). Plastic cathe-
ters are temporarily inserted into the gland and are used as
a delivery system for an Iridium source of high activity.
Patients receiving this therapy for PCa are treated 4 times
over a 36-hour hospital stay [13,14].
Analysis of Medicare data shows that brachytherapy is
replacing radical prostatectomy (RP) as the treatment of
choice for early stage PCa [13]. An important component
in the consideration of treatment options for PCa is the
impact on QOL [5]. Ideally a patient would select a treat-
ment modality that maximizes both survival and QOL.
Evolving treatment options make such choices more com-
plex. Because rates of tumor control appear to be remark-
ably similar across treatment approaches, studies
comparing QOL outcomes are of great importance [15].
One hundred fifteen articles focused on IMRT were iden-
tified using the National Library of Medicine data-base
http://www.pubmed.com; however, few studies focused
on QOL in patients receiving IMRT for prostate cancer.
Kupelian and colleagues [16] studied QOL of 51 prostate
cancer patients treated with IMRT using the Expanded
Prostate Cancer Index Composite to evaluate QOL. No
other variables were measured; thus, predictors of QOL
were not addressed. The objective of this article is to report
physical and psychosocial predictors of QOL variables in
men who are diagnosed with prostate cancer and receive
radiation treatments including IMRT + HDR or IMRT +
seed implantation. Figure 1 describes proposed relation-
ships among study variables. The main research question
is: What proportion of the variance in each dimension of
quality of life (physical function, role performance-physi-
cal, role performance-emotional, bodily pain, vitality,
social function, mental health and general health) is pre-
dicted by demographic variables, physical symptoms,
coping style, perceived stress, anxiety, and self-efficacy in
men receiving IMRT + HDR or IMRT + seed implantation?
Figure 1
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Methods
Sample and setting
Subjects were 122 men diagnosed with prostate cancer,
who could hear, understand and speak English, and were
receiving either (a) IMRT + HDR treatment (n = 67) or (b)
IMRT + radioactive seed implantation (n = 56). Patients
with organ confined prostate cancer (Stage: T1c-T2b;
Gleason grade 6–9; PSA <20) were staged clinically by his-
tory, physical exam, digital rectal examination, and serum
PSA measurement. Additional studies, including CT scan,
bone scan, and endorectal MRI, were obtained as clini-
cally indicated. Patients treated with brachytherapy
received external beam therapy delivered to a limited field
encompassing the prostate gland and seminal vesicles
with 1.8 Gy fractions to a total dose of 50.4 Gy. IMRT was
delivered with arc therapy using a multileaf modulating
collimator (NOMOS Corporation, Sewickley, PA).
Patients then received a 90 Gy palladium-103 interstitial
implant using a modified peripheral loading technique.
Those patients with a prior history of transurethral resec-
tion, those with glands >50 cc, and those with AUA scores
>20 received a 20Gy HDR temporary catheter implant.
The setting, a medical center located in the mid-Atlantic
region of the United States, has extensive experience in
prostate interstitial brachytherapy and intensity modula-
tion techniques. Patients were recruited during their regu-
larly scheduled visits or follow-up appointments for
radiation therapy for prostate cancer.
Instruments
Biographic questionnaire
Subjects completed a 12-item biographic questionnaire
including questions about age, income, education, work
status, race, medications, and health habits including
smoking, alcohol use, and exercise. The date the patient
began radiation therapy as well as the date the patient
completed the questionnaire was noted in order to calcu-
late the length of time since a patient began radiation
therapy.
Quality of life
The Medical Outcome Study Short Form Health Survey
(SF-36), a 36-item measure of health status that is rooted
in psychometric theory, is commonly used to measure
QOL in clinical populations [2]. The SF-36 measures 8
dimensions of current health-related QOL: Physical Func-
tion (limitations to activities); Role Performance with
Physical Limitations; Role Performance (ability to work
and accomplish daily activities) with Emotional Limita-
tions; Bodily Pain and pain related limitations; Vitality
(feelings of energy or fatigue); Social Function (interfer-
ence with normal social activities); Mental Health (nerv-
ousness and depression); and General Health. In
instrument standardization, Cronbach's alpha reliabilities
for the SF-36 ranged from .63 to .94 [17]. Higher scores
indicate better health. In this study, reliability for the 8
dimensions of QOL ranged from .68 to .91.
Physical symptoms
Although the Radiation Therapy Oncology Group and the
European Organization for Research and Treatment of
Cancer (RTOG/EORTC) grading system [18] is currently
used to measure symptoms in the setting where data were
collected, the Prostate Symptom Self-Report (PSSR) was
developed for this study and used to assess patients' per-
ceptions of their symptoms. This was done in view of the
reported low agreement between medical professional rat-
ings and patient ratings of symptoms [18]. The PSSR is an
11-item symptom questionnaire that assesses the fre-
quency, severity and amount of bother of urinary, bowel
and sexual symptoms experienced during the past month.
Frequency is expressed as number of days per week the
symptoms occur. Subjects rate each question from 0 –
never to 6-most or all of the time (5–7 days). Severity and
bothersomeness are measured by a single item for each
symptom cluster. The response set for bothersomeness
and severity ranges from no bother (or not severe at all) =
0 to extremely bothersome (or extremely severe) = 4.
Higher scores indicate more symptoms. Two open-ended
questions assess the quality of symptoms, asking subjects
to circle word descriptors of the symptom, and to list any
other symptoms (bladder, bowel and sexual) they experi-
enced. In addition, open-ended questions permit the
addition of other symptoms and word descriptors for
symptoms in these three domains. Validity of the scale
was supported by its development based on a review of
the literature describing symptoms reported by men dur-
ing and following treatment for prostate cancer. Higher
scores indicate increased symptoms. Cronbach's alpha
reliabilities for the urinary, bowel and sexual symptom
subscales were .85, .80 and .69 respectively.
Psychosocial factors
Mood is conceptualized as a fluctuating state of affect that
includes the dimensions of tension-anxiety, depression-
dejection, anger-hostility, vigor-activity, fatigue-inertia
and confusion-bewilderment. The Profile of Mood States
(POMS), assessing a person's perception of feeling and
affect measures these six dimensions of mood [20]. Sub-
jects are asked to read the list of words that describe feel-
ings people have, then report how they have been feeling.
Responses are scored from 0 (Not at all) to 4 (Extremely).
Higher scores indicate greater mood disturbance. Areas of
research that have provided evidence for the predictive
and construct validity of the POMS include brief psycho-
therapy studies, drug trials, studies of response to emo-
tion-inducing conditions and studies of concurrent
validity coefficients and other POMS correlates [20]. Sum-
ming the subscales produced a Total Mood DisturbanceHealth and Quality of Life Outcomes 2004, 2 http://www.hqlo.com/content/2/1/28
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Score (TMDS) score. Cronbach's alpha reliability for the
scale in this study was .93.
Coping was measured with the Ways of Coping Scale
(WOC), a 66-item self-report scale that assesses thoughts
and actions used to cope with stressful encounters of eve-
ryday living [8]. Two subscales, Problem-Focused Coping
and Emotion-Focused Coping, were used in this study.
Problem-Focused Coping is a composite of scores from
four subscales: confrontive coping, seeking social support,
problem solving, and positive reappraisal. Emotion-
Focused Coping is a composite of scores from three
dimensions: distancing, accepting responsibility, and
escape-avoidance. Items are rated on a 5-point frequency
scale indicating how often each strategy was used over the
preceding 4 weeks and range from 0 = "does not apply" to
4 = "used a great deal." Higher scores indicate increased
coping. In a community sample, Cronbach's alpha relia-
bility coefficients for the subscales ranged from .61 to .79.
Validity was supported by the scale's inclusion of strate-
gies described by individuals as those used to cope with
stressful situations [8]. Coefficient alpha of the subscales
in the current sample was .89 for Problem-Focused Cop-
ing, and .82 for Emotion-Focused Coping.
The Perceived Stress Scale (PSS), a 14-item measure of the
degree to which situations in one's life are appraised as
stressful [21], was used to measure stress. Items are rated
on a 5-point frequency scale ranging from 0 = "never" to
4 = "very often" for how often in the past month the sub-
ject has experienced stress-related feelings and thoughts. A
total perceived stress score is obtained by reversing the
scoring on the positive items and summing responses
across the 14 items. Higher scores indicate more stress.
Coefficient alpha reliabilities for the scale were .84 to .86
in three community samples [21]. Validity was supported
in the scale's ability to predict depressive and physical
symptoms, and utilization of health services. Cronbach's
alpha estimate for the PSS data in the sample reported in
this paper was .88.
Anxiety was measured with the SCL-90 Anxiety Subscale,
a 10-item self-report scale, indicating the degree to which
a person was distressed by a specific problem in the past
week. The measure uses a 5-point response scale, ranging
from "not at all" to "extremely." Higher scores indicate
more anxiety. Cronbach's alpha coefficients for reliability
of this subscale in a chronically ill population were .79 to
.91. Good validity evidence has been reported [22]. Coef-
ficient alpha of the SCL-90 anxiety subscale in our sample
was .90.
Strategies Used by Patients to Promote Health (SUPPH),
a 29-item self-report scale, has previously been used to
measure self-care self-efficacy in patients with cancer
[23,24]. Confirmatory factor analysis supports three
dimensions of SUPPH: Positive Attitude, Stress Reduc-
tion, and Making Decisions (Owen, SV & Lev, EL: Con-
firmatory factor evidence for the SUPPH. Presented at the
13th Annual Scientific Sessions of the Eastern Nursing
Research Society. Atlantic City, NJ, 4/2/01). The subject is
asked to rate the degree of confidence he has in carrying
out specific self-care behaviors. Each item of the SUPPH is
rated on a 5-point scale of confidence from 1 = "very little"
to 5 = "quite a lot." Higher scores indicate greater self-care
self-efficacy. The instrument is scored by calculating mean
response across all items for each subscore. Estimates of
internal consistency ranged from .94 to .96, and validity
evidence has been reported [23]. In this study, Cronbach's
alpha reliability for the positive attitude, stress reduction
and making decisions subscales were .94, .88 and .77
respectively.
Procedures
Members of the interdisciplinary research team collabo-
rated to develop and implement the study. IRB approval
was granted by the University and Medical Center with
which co-investigators are affiliated. Students in a college
of nursing who were research assistants in the study
attended an 8-hour training session given by the principal
investigator to assure that procedures used were congru-
ent with study protocol. They were familiarized with the
method of obtaining informed consent, content of ques-
tionnaires, and how to answer participant questions.
Role-playing was used to familiarize each research assist-
ant with application of the protocol.
Initial recruitment was conducted by the physician, nurse,
or social worker in the radiation oncology treatment area.
Potential participants were identified, the study was
briefly described and patients were asked about their
interest in learning more about the study. A co-investiga-
tor or research assistant met with those who were
interested and fully explained the study. Informed con-
sent was obtained from those willing to participate. The
participant then completed questionnaires in a private
area of the treatment center. The co-investigator or
research assistant remained available to assist or answer
any questions and collected completed questionnaires.
Participation occurred at one time point and lasted
approximately one-hour.
Data analysis
Data were collected on 122 men, but some data were
missing on 59 of those. Descriptive data analysis was per-
formed on 122 subjects who received IMRT + HDR (n =
66) or IMRT + seed implantation (n = 56). Regression
analyses were conducted on the 63 cases with complete
data. Independent variables included age, income, RTOG/
EORTC, PSSR, Problem Focused Coping and EmotionHealth and Quality of Life Outcomes 2004, 2 http://www.hqlo.com/content/2/1/28
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Focused Coping subscales of the WOC, PSS, Anxiety Sub-
scale of the SCL-90, and subscales of the SUPPH: Positive
Attitude, Stress Reduction, and Making Decisions.
Dependent variables were each of the eight SF-36 scales:
Physical Function (limitations to activities); Role Per-
formance with Physical Limitations; Role Performance
(ability to work and accomplish daily activities) with
Emotional Limitations; Bodily Pain and pain related lim-
itations; Vitality (feelings of energy or fatigue); Social
Function (interference with normal social activities);
Mental Health (nervousness and depression); and Gen-
eral Health. Data were missing for a variety of items in sev-
eral scales; therefore, subscale scores were created as
means (rather than sums) for use in regression analyses.
Eight regression models were built to assess the degree to
which the independent variables predicted each of the
eight QOL indicators as measured by each of the SF-36
subscale scores. Because complete data were available on
a small sample: IMRT + HDR (n = 31) and IMRT +seed
implantation (n = 32), there was insufficient power for
meaningful significance testing. However, Cohen [25]
noted that effect size (e.g., R2) is paramount in assessing
intervention outcomes when small sample size shrinks
the power of statistical tests. Cohen [25] suggested the fol-
lowing rough guidelines for R2 effect sizes: small (= .02),
medium (= .13), and large (= .26). Initial regressions
showed that the Total Mood Disturbance Score, calculated
from the POMS, was highly correlated with other predic-
tors. Because collinearity leads to undependable signifi-
cance tests and unreliable regression coefficients [26]
subsequent regression models did not include the POMS.
Because of the small sample size, a liberal two-tailed alpha
of .10 was used in interpreting predictor variables.
Results
There were no significant differences between treatment
groups in age (t = .55; p = .58), race (U = 1785; p = .50),
work status (U = 1843; p = .97), income (U = 1006; p =
.07) or living together with a significant other (U = 1811;
p = .83). There was a significant difference in education (U
= 1379; p = .02), with 69% of the IMRT+HDR group hav-
ing completed some college, compared to 51% of the
IMRT+ seeds group.
The mean age of study participants was 72 years (range 51
– 84 years). The majority of participants was married (n =
91), white (n = 112), had some college education (n = 74),
and was retired (n  = 94). Median income was in the
$40,000 to $49,000 range. The mean length of time since
beginning radiation treatment for prostate cancer was 10
months (median 8 months), with a range of less than one
month to 31 months.
Table 1 presents the means and standard deviations of
both the scale scores and mean scores for independent
variables and QOL subdimensions of patients receiving
IMRT+HDR or IMRT + seed implantation.
Table 1: Means and Standard Deviations for QOL Indicators of Patients with Prostate Cancer Receiving IMRT + HDR or IMRT + seed 
implantation
Treatment groups HDR seed implantation
Scale Sum Scale Mean Scale Sum Scale Mean
Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Measure
Stress 15.2 (9.3) 1.04 (.65) 15.4 (8.7) 1.20 (.72)
Mood 2.82 (5.0) .42 (.63) 3.4 (5.8) .48 (.78)
Anxiety 2.7 (5.3) 0.26 (.56) 2.6 (4.6) 0.30 (.54)
PFC 25.8 (12.5) 0.10 (.51) 24.7 (13.7) 1.06 (.56)
EFC 13.2 (8.7) 0.70 (.48) 14.3 (8.2) 0.79 (.45)
Positive attitude 52.5 (14.2) 3.63 (1.09) 49.8 (13.7) 3.51 (.98)
Stress Reduction 16.1 (6.7) 2.63 (.94) 15.7 (7.1) 2.82 (1.02)
Making decisions 10.0 (3.7) 3.23 (1.27) 9.6 (4.0) 3.20 (1.5)
Urinary symptoms 6.9 (.77) 1.67 (2.0) 5.8 (.40) 1.37 (3.1)
Bowel symptoms 4.0 (.56) 1.29 (1.3) 3.8 (.39) 1.25 (1.9)
Sexual symptoms 6.2 (.91) 2.03 (2.6) 6.8 (1.0) 2.12 (2.9)
Physical function 24.8 (5.8) 26.3 (3.4)
Role-physical 7.0 (1.5) 6.7 (1.6)
Role-emotional 5.5 (1.0) 5.4 (1.0)
Bodily pain 10.2 (2.3) 10.0 (2.0)
Vitality 16.8 (4.3) 16.3 (4.8)
Social function 9.0 (1.7) 8.8 (1.5)
Mental health 25.5 (3.9) 24.3 (4.6)
General health 20.1 (3.4) 19.1 (3.4)
PFC = Problem-focused coping; EFC = Emotion-focused copingHealth and Quality of Life Outcomes 2004, 2 http://www.hqlo.com/content/2/1/28
Page 7 of 11
(page number not for citation purposes)
In arranging the regression models, an essential question
was whether to combine the treatment samples or analyze
them separately. To answer this question, Chow [27] tests
were performed. The Chow [27] test asks whether two (or
more) groups behave differently for a given regression
model. For all eight SF-36 regressions, there were dramatic
group differences, with effect sizes (R2) ranging from .19
to .39. In other words, upwards of 39% of the variation in
the regression models owed to differences between the
two treatment groups. As can be seen in Table 3, there
were sometimes large group differences in the amount of
explained variation, and often important differences in
which predictors were useful. For example, in predicting
SF36 General Health, 54% of the variance was explained
for the IMRT + HDR group, but 34% for the IMRT + seed
group. Note also that significant predictors also differed:
PSS and bowel symptoms for the IRMT + HDR group, and
problem-focused coping for the IRMT + seed group.
Despite the important group differences, all regression
models showed strong effects, with the smallest R2 of .24
(predicting SF36 Role Performance with Physical Limita-
tions for the IRMT + seed group). This effect size is about
the same as Cohen's suggestion about a "large" effect for a
regression model. All other R2s were considerably higher,
peaking at .85 (predicting SF36 Mental Health for the
IRMT + seed group.
Discussion
Regression models were used to evaluate physical and
psychosocial predictors of QOL as measured by the SF-36
for patients receiving IMRT + HDR or IMRT + seed
implantation. Patterns of predictors of QOL variables dif-
fered between treatment groups. Large between-group
treatment effect sizes on physical function, role perform-
ance (physical limitations), role performance (emotional
limitations), bodily pain, social function and mental
health were observed. Between-group treatment effect
sizes resulted from different types of treatment: IMRT +
HDR (n = 31) and IMRT +seed implantation (n = 32).
Most physicians would be comfortable categorizing a
moderately large effect as clinically important [28].
Urinary symptoms were related to seven of the eight qual-
ity of life subscales and bowel symptoms were related to
six. Sexual symptoms were related only to physical func-
tion. The number of significant relationships between
psychosocial variables and indicators of QOL exceeded
the number of relationships among symptoms and QOL.
Psychosocial variables were related to physical function,
role function (both physical and emotional), bodily pain,
general health, vitality, social function, and mental
health. Physical symptoms were related to subjects' gen-
eral health and mental health suggesting that psychoso-
cial variables associate strongly with prostate cancer
patients' reports of quality of life. These data supported
Bandura's [10] assertion that psychosocial factors may
determine QOL.
Perceived stress was related to subjects' physical function,
role function, bodily pain, role performance with emo-
tional limitations, and mental health. Positive attitude
was related to subjects' mental health. Making decisions
was related to role (emotional limitations), vitality and
mental health. Roth and associates [9] examined the prev-
alence of anxiety and depression in a sample of 93 men
with prostate cancer. They found that 32.6% scored above
the anxiety clinical cutoff score and 15.2% scored above
the cutoff for depression. Bandura [10] described self-effi-
cacy as the exercise of control, and perceived control has
been identified as a mediator of successful adjustment in
cancer patients [29]. The importance of positive attitude
and stress reduction for cancer patients has been docu-
mented [30,31]. Efficacy expectations – beliefs that one
has some mastery over events and can meet challenges as
they occur – are learned. Psychosocial interventions
taught to cancer patients have reduced psychological dis-
tress and symptoms, enhanced QOL [31], and increased
psychological adjustment and survival [31-36].
As shown in previous studies, we found that symptoms
were negatively associated with QOL. We also found that
the relationships between specific symptoms and subdi-
mensions of QOL varied by treatment. In men who
received IMRT + seed implantation, urinary, bowel, and
sexual symptoms were negatively related to mental
health. Urinary retention is a frequently reported compli-
cation following radioactive seed implantation of the
prostate [37]. Unlike other studies that have reported no
difference in QOL by type of treatment, we found large
treatment effects for seven of the eight subdimensions of
QOL measured in this study.
In men who received IMRT + HDR, sexual symptoms were
negatively related to role function; bowel symptoms were
negatively related to general health; and, urinary symp-
toms of men receiving HDR were negatively related to
social function. Patients receiving different treatment
modalities for prostate cancer experience different
symptoms.
Although some researchers reported that hormonal ther-
apy may result in decreased quality of life outcomes [38],
other researchers noted that those treated by androgen
deprivation were not significantly worse after treatment
[39]. After a delay of 15 days after implantations, urinary
morbidity was reported in 76% of patients who received
brachytherapy [40]. This development of urinary morbid-
ity was the highest 1–3 months after treatment before
gradually decreasing at 6 months after treatment. Vincini
and associates [40] assessed 161 patients with locallyHealth and Quality of Life Outcomes 2004, 2 http://www.hqlo.com/content/2/1/28
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advanced PCa treated with external-beam radiation ther-
apy combined with HDR brachytherapy; 27% of patients
developed impotence at a median interval of 1 year after
treatment. Information on QOL outcomes of radiation
therapy for patients with prostate cancer suggests that
there are treatment related differences, thus health care
providers should more fully inform patients with prostate
cancer regarding what to expect from their treatments.
Conclusions
Future research
This cross-sectional study was conducted with men diag-
nosed with organ confined prostate cancer who were
Table 2: Multiple R2, standardized regression coefficients and 2-tailed p values for predictors of QOL
Treatment groups HDR Seed implantation
R2 Beta pR 2 Beta p
Measure Predictor Predictor
SF36-physical function .48 .51
Age -.39 .09 Income .55 .02
PSS -.53 .07 EFC -.42 .10
PFC -.54 .10
EFC .78 .06
POSATT .53 .06
MAKDEC -.49 .07
SF36-physical role .50 .24
Sexual symptoms .33 .09
SF36-emotional role .48 .51
Age -.39 .09 Income .55 .02
PSS -.53 .07 EFC -.42 .10
PFC -.54 .10
EFC .78 .06
POSATT .53 .06
MAKDEC -.49 .07
SF36-bodily pain .48 .51
Age -.39 .09 Income .55 .02
PSS -.53 .07 EFC -.42 .10
PFC -.54 .10
EFC .78 .06
POSATT .53 .06
MAKDEC -.49 .07
SF36-general health .54 .34
PSS -.58 .04 PFC .52 .10
Bowel symptoms -.59 .03
SF36-vitality .37 .36
SF36-social function .74 .71
Urinary symptoms -.41 .04 Age .43 .02
SF36-mental health .71 .85
PSS -.40 .07 Age .26 .05
Anxiety -.5 .05 PSS -.34 .10
Anxiety -.60 .01
Urinary 
sympto
ms
-.28 .05
Bowel 
sympto
ms
.39 .03
Sexual 
sympto
ms
-.35 .01
MAKD
EC
.42 .02
PSS = Perceived Stress scale; PFC = Problem-focused coping; EFC = Emotion-focused coping; POSATT = Positive attitude subscale of SUPPH; 
MAKDEC = Making decisions subscale of SUPPH.Health and Quality of Life Outcomes 2004, 2 http://www.hqlo.com/content/2/1/28
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receiving or had completed radiation treatments with
IMRT + HDR or IMRT + seed implantation. Therefore, no
pre and post-treatment comparisons could be made
between subjects' QOL. Researchers have noted that the
best way of assessing post-treatment issues is the pre-mor-
bid state of the patient himself; therefore longitudinal
studies of QOL of prostate cancer patients should be con-
ducted [6].
Further study of physical and psychosocial predictors of
QOL should be conducted with homogeneous groups of
patients receiving treatments for prostate cancer. Analyses
of Medicare data show that brachytherapy is replacing
radical prostatectomy as the treatment of choice for early
stage prostate cancer [13]. QOL plays an important role in
the consideration of treatment options for PCa. Selecting
a treatment for prostate cancer that maximizes both sur-
vival and QOL is complex. Because rates of tumor control
appear to be similar across different treatment
approaches, studies comparing QOL options are of great
importance [15]. Longitudinal studies are needed to com-
pare patients receiving radiation therapies for prostate
cancer with those receiving radical prostatectomy. Data
indicating whether or not patients have received hormo-
nal therapy should be included. Larger sample sizes are
also needed to explore predictors of QOL by testing how
well a hypothesized model fits empirical data [41].
The sample size of the study reported here was greatly
reduced due to the amount of missing data. Knapp [41]
noted that the best way to handle missing data is to plan
in advance how to prevent the data from being missing.
Telephone interviews have been used as a mechanism for
assessing patients after radiotherapy treatment [42].
Future research conducted by telephone interviewers who
enter data directly into the computer as they conduct the
telephone interview may prevent much of the missing
data noted in the current study, in which respondents
filled out surveys by themselves.
Stegina and associates [43] identified informational needs
as a priority for men with prostate cancer. In a context
where there is uncertainty or ambiguity about treatment,
men may experience a high need for informational sup-
port. Informational resources for men with prostate can-
cer are relatively new, and still emerging. Thus, research is
suggested that compares QOL of men receiving radiation
therapies for prostate cancer with those receiving radical
prostatectomy in order to inform decision-making by
patients and their families.
Active coping, which includes activities such as problem
solving, expression of emotion, participation in health
enhancing behaviors, and information seeking, is thought
to have beneficial health effects [10]. Previous studies
revealed that cancer patients use coping strategies to
adjust to their diagnosis and treatment. Patients with
breast cancer who were given an intervention to increase
self-efficacy had decreased perceived stress, decreased self-
reported symptoms, and perceptions of increased QOL
[44]. Graves conducted a meta-analysis of 38 studies eval-
uating QOL outcomes after psychosocial interventions
based on self-efficacy were given to cancer patients and
reported overall improvement in QOL outcomes for adult
cancer patients [36]. Providing efficacy-enhancing inter-
ventions for patients receiving cancer treatment may
decrease patients' perceived stress and self-reported symp-
toms, and increase patients' positive perception of QOL.
Relevance to practice
Psychological variables were strong predictors of all
domains of quality of life examined in this study.
Researchers reported that 38% of prostate cancer patients
who seek support reported psychological distress [45].
Psychological variables had a greater effect on prostate
cancer patients' quality of life and distress than disease
status but were less frequently treated [46,47]. Psycholog-
ical problems present issues beyond merely poor QOL.
Cancer patients with previous emotional problems faced
a 2.6 times greater hazard of dying within the first 19
months after diagnosis than patients without prior prob-
lems [47]. Although prostate cancer is known to be asso-
ciated with psychological distress, such as anxiety and
depression, many patients with these symptoms fail to
meet criteria for a psychiatric disorder [48]. Patients may
be reluctant to bring up their distress, leading physicians
to underestimate them and thus reduce optimal symptom
control. Early detection of such distress may permit psy-
chosocial interventions that may have a substantial
impact on preventing more serious psychological prob-
lems [48].
Significant between-treatment differences were observed
in this study for all dimensions of QOL. With better infor-
mation on physical and psychosocial predictors of QOL,
health care providers may be better able to educate
patients who are contemplating receiving IMRT + HDR or
IMRT + seed implantation therapy for prostate cancer.
Learning theory suggests that people are interested in
information that will improve their well being, help them
to understand their immediate problems, and anticipate
their future [49]. Findings of this study may guide health
care providers who provide patients and families with
information that enables them to understand QOL out-
comes of IMRT with either HDR or seed implantation and
make more informed treatment choices.
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